USTR Extends China 301 Exclusions for Certain COVID-related Products through September

On May 17, 2023, the Office of the U.S. Trade Representative published in the Federal Register (88 FR 31580) Notice of Product Exclusion Extensions: China's Acts, Policies, and Practices Related to Technology Transfer, Intellectual Property, and Innovation.

In prior notices, the U.S. Trade Representative modified the actions in the Section 301 investigation of China’s acts, policies, and practices related to technology transfer, intellectual property, and innovation by excluding from additional duties certain medical-care products needed to address COVID, and subsequently extended certain of these exclusions. The current COVID exclusions -- covering 81 medical-care products -- are scheduled to expire on May 15, 2023. This notice announces the U.S. Trade Representative's determination to provide a 16-day transition period for all COVID exclusions, extending them through May 31, 2023, and to extend 77 of the COVID exclusions through September 30, 2023.